Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Clinical PET/MR Imaging in Dementia and Neuro-Oncology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clinical PET/MR Imaging in Oncology: Future Perspectives

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. PET/MR Imaging: Clinical Applications

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. PET/MR Imaging in Musculoskeletal Disorders

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Soluble Markers of Interleukin 1 Activation as Predictors of First-Time Myocardial Infarction in HIV-Infected Individuals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. FDG-PET/CT in the surveillance of head and neck cancer following radiotherapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Surgical Management, Preoperative Tumor Localization, and Histopathology of 80 Patients Operated on for Insulinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Urokinase-type plasminogen activator receptor (uPAR) overexpression is an important biomarker for aggressiveness in cancer including prostate cancer (PC) and provides independent clinical information in addition to prostate-specific antigen and Gleason score. This article focuses on uPAR PET as a new diagnostic and prognostic imaging biomarker in PC. Many preclinical uPAR-targeted PET imaging studies using AE105 in cancer models have been undertaken with promising results. A major breakthrough was obtained with the recent human translation of uPAR PET in using 64Cu- and 68Ga-labelled versions of AE105, respectively. Clinical results from patients with PC included in these studies are encouraging and support continuation with large-scale clinical trials.

OriginalsprogEngelsk
TidsskriftPET Clinics
Vol/bind12
Udgave nummer2
Sider (fra-til)243-255
Antal sider13
ISSN1556-8598
DOI
StatusUdgivet - apr. 2017

ID: 55064550